Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
7 Veni-beurzen voor MDL-onderzoek
aug 2024 | Hepatologie, IBD, Immuuntherapie, Maag-darm-leveroncologie, Pancreatitis, Parasitaire infecties